Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream

Abstract

INTRODUCTIONThere are various approaches to the treatment of cutaneous tumors; one of them is treatment with imiquimod, a synthetic toll-like receptor agonist with a low molecular weight that offers a topical, noninvasive, and non-surgical therapeutic option. The main objective of our study was to provide data on 89 patients who used a 5% imiquimod cream for the treatment of cutaneous tumors at the Cutaneous Oncology Group of the Dermatology Department of Hospital das Clinicas from 2003 to 2008.MATERIALS AND METHODSHere, we present our experience in the treatment of 123 cutaneous tumors of various types, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Bowen’s disease, erythroplasia of Queyrat, Paget’s disease, and trichoepithelioma, with 5% imiquimod cream from 2003 to 2008 in the Cutaneous Oncology Group of the Dermatology Department of Hospital das Clinicas. Patients were divided into two separate groups according to their diagnosis and comorbidities; these comorbidities included epidermodysplasia verruciformis, xeroderma pigmentosum, albinism, basal cell nevus syndrome, Brooke-Spiegler syndrome, HIV, chronic lymphocytic leukemia, B-cell lymphoma, and kidney transplantation. Treatment duration, response to imiquimod, follow-up, recurrence, and local and systemic reactions associated with use of the drug were analyzed. Epidemiological data were obtained and cure rates were calculated.RESULTSThe ratio of women to men was 1.28:1, and the mean age was 63.1 years. Tumors were located mainly on the face, back, trunk, and legs. For patients with comorbidities, the overall cure rate was 38%. These specific patients demonstrated cure rates of 83.5% for superficial BCC and 50% for Bowen’s disease. Aggressive BCC and superficial and nodular BCC did not present a good response to treatment. Trichoepitheliomas and nodular BCC showed a partial response, and erythroplasia of Queyrat showed a complete response. For patients without comorbidities, the overall cure rate was 73%. For these patients, the cure rates were 85.7% for superficial and nodular BCC, 88% for superficial BCC, 57% for Bowen’s disease, 50% for nodular BCC, and 50% for aggressive BCC. One SCC lesion demonstrated a complete response, and tumors caused by Paget’s disease and erythroplasia of Queyrat presented a partial response. None of the tumors considered as clinically cured recurred. Thirty-seven lesions demonstrated no response to imiquimod. Having a cutaneous comorbidity, high-risk tumors such as mixed aggressive BCC (sclerodermiform or micronodular), nodular BCC, or Bowen’s disease, and presenting no local reaction to imiquimod were considered as risk factors for a worse prognosis. We demonstrate that patients with no response to imiquimod, even when they demonstrated no local reaction, can undergo another cycle of six weeks of imiquimod treatment and show a complete response. The healing pattern led to good cosmetic outcomes, and the side effects were tolerable.CONCLUSIONSOur experience confirms imiquimod as an effective treatment op...

Imiquimod 5% Cream for The Treatment of Actinic Keratosis of The Eyelid

“…Lesion was resolved after 6-week period. Systemic side effects such as flu-like symptoms, nausea, headache, myalgia, fatigue, and fever that have been reported in the literature (18,19) were not observed in our patient.…”

BritishAssociation ofDermatologists' guidelines for the management of squamous cell carcinomain situ(Bowen's disease) 2014

“…51 Another study from Brazil reported that only 57% of patients (four of seven) with SCC in situ, without any significant comorbidities such as immunosuppression, cleared following a mean of 6Á1 weeks of treatment. 52 Single cases or small case series suggest that different regimens such as cyclical treatment 53 might be useful, and also that imiquimod might be effective for large facial lesions. 54 These, along with lower-leg lesions, 50 are typically those that pose the greatest therapeutic challenge.…”

Optical Coherence Tomography Imaging of Erythroplasia of Queyrat and Treatment with Imiquimod 5% Cream: A Case Report

“…In our case study, topical therapy with imiquimod 5% effectively treated the patient's EQ as evidenced clinically and by follow-up OCT. Several other case reports have also demonstrated the successful treatment of EQ with imiquimod 5% both in the presence and absence of HPV type 16 infection [3,16,17,18,19]. The results of these case reports together suggest that both the antiviral and antitumour effects of imiquimod are important in its ability to treat EQ.…”